Carga de la prueba y estándar mínimo de la prueba por indicios en materia de responsabilidad por los daños ocasionados por un producto farmacéutico defectuoso (a propósito de la STJUE de 21 de junio de 2017)
ISSN: 1989-4570
Year of publication: 2017
Volume: 9
Issue: 2
Pages: 709-724
Type: Article
More publications in: Cuadernos de derecho transnacional
Abstract
The ECJ judgment of 21 June 2017 (Second Chamber), Sanofi Pasteur MSD SNC, C-621/15, addresses the compatibility of the so-called “evidence for presumptions or indications” with art. 4 of Directive 85/374 on liability for damage caused by defective products, in circumstances where the state of science does not allow to demonstrate, but does not exclude, the relation between a pharmaceutical product and the damage. The judgment examines the conditions and limits which it must comply with in order to constitute a valid method of lifting the burden of proof on the defectiveness of the product, the damage caused and the causal link which article 4 of the Directive imposes on the injured
Bibliographic References
- A. de La Oliva Santos, Curso de Derecho procesal civil II. Parte especial, con I. Díez-Picazo Giménez y J. Vegas Torres, 3ª ed., Madrid, Editorial Universitaria Ramón Areces, 2016
- M. A. Parra Lucán, Daños por productos y protección del consumidor, Bosch, Barcelona, 1990
- S. Ramos González, “La responsabilidad por medicamento en el derecho alemán”, Indret: Revista para el Análisis del Derecho, nº 1, 2003